Medsamic

Tranexamic Acid, the active ingredient in Medsamic, is an antifibrinolytic presented as an oral formulation for systemic use. It helps reduce excessive bleeding in several clinical situations, including menstrual, surgical, and trauma‑related hemorrhage.\n\nGNH India supplies Medsamic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medsamic is an antifibrinolytic that reduces pathological bleeding across several conditions.\n\nHeavy menstrual bleeding: decreases menstrual blood loss and improves quality of life.\nHereditary angioedema: limits swelling episodes by stabilising clots in the microvasculature.\nTrauma‑related bleeding: controls acute hemorrhage in injured patients.\nDental surgery bleeding: minimizes intra‑operative and post‑operative bleeding during oral procedures.

Medsamic may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Nausea or vomiting\n- Diarrhoea or abdominal discomfort\n- Headache or dizziness\n- Fatigue or menstrual irregularities\n\nSerious or Rare Side Effects:\n- Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism\n- Visual disturbances, including blurred vision\n- Severe allergic reactions, including rash, swelling or anaphylaxis

Before prescribing Medsamic, clinicians should consider several safety measures.\n\nAssess thrombotic risk: evaluate patient history of clotting disorders.\nMonitor renal function: adjust use in patients with impaired kidney function.\nAvoid in active intravascular clotting: contraindicated when clot formation is ongoing.\nUse with caution in pregnancy: limited data, weigh benefits against potential risks.\nDiscontinue before surgery: follow peri‑operative guidelines for timing.\nStore at ambient temperature: keep in original container, protect from moisture and heat.

Medsamic can interact with other medicines, requiring attention to avoid reduced efficacy or increased risk.\n\nMajor Interactions (Avoid):\n- Combined hormonal contraceptives: heightened risk of thrombotic events.\n- Thrombolytic agents (e.g., alteplase): antagonises intended clot‑dissolving effect.\n- Anticoagulants (e.g., warfarin, DOACs): may diminish anticoagulant activity.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: increased potential for gastrointestinal irritation.\n- Antihypertensives: possible additive effect on blood pressure control.\n- Diuretics: may alter renal clearance of tranexamic acid.